"It is noteworthy that GLP-1 drugs for diabetes became available in 2007 and long-term records of these drugs haven't shown any increased signs of adversity, apart from nausea and constipation or diarrhoea in about 5 to 10 per cent of people and an increased risk of gallstones." Some of the more serious concerns around semaglutide are linked to pancreatitis, acute kidney injury and anxiety
To be a candidate for receiving such a medication for weight loss, a person generally needs to meet one of the following criteria, as assessed by a medical professional: For non-Asians: A BMI of 30 or greater, or a BMI of 27 or greater along with health complications of being overweight
Daniel Drucker, a University of Toronto researcher involved in early GLP-1 development, said scientists are investigating anecdotal reports from patients describing changes in mood, anxiety and cognition while taking the medications, according to The Washington Post
We meticulously manage your insurance paperwork, providing support with prior authorization support and appeals when necessary
/assets/production/practices/3280152d22c7599df4208c7f13bd6f106ba2a939/images/2788239.jpeg)
